Mar 26, 02:55 PM

Bluebird Bio, Chemours Face Financial Scrutiny for 2022 After SEC and DOJ Probes

Gene therapy maker bluebird bio and chemical company Chemours are facing financial scrutiny after accounting errors and investigations. Bluebird plans to revise its financial statements for 2022 and part of 2021, while Chemours is being probed by the SEC and DOJ, with top executives on leave and financial revisions revealed.

#Chemours #Bluebird #SEC #DOJ

Written with ChatGPT (GPT-3).

Sources

Open Outcrier@OpenOutcrier
2 years ago
$CC (-8.9% pre) The Chemours Co (CC) Faces Net Loss in 2023 Amidst Litigation Charges - Y Finance https://t.co/LO6fsKZ8Ws
Barron's@barronsonline
2 years ago
Chemours Stock Is Plunging Despite Earnings Beat. There Are Two Reasons. https://t.co/IM3MEdAFVW
Reuters Business@ReutersBiz
2 years ago
Chemours reveals certain financial revisions after internal review https://t.co/iKDZ5Xweu8 https://t.co/eb460sVcCy

Additional media

Image #1 for story bluebird-bio-chemours-face-financial-scrutiny-2022-after-sec

Bluebird Bio, Chemours Face Financial Scrutiny for 2022 After SEC and DOJ Probes

Sources

Additional media

Similar Stories